Tidying up US stomach cancer approvals
A US adcom will next month try to unravel confusion about PD-L1 status in first-line gastric cancer.
A US adcom will next month try to unravel confusion about PD-L1 status in first-line gastric cancer.
After several disappointments Bristol at last turns its Lag3/PD-1 combo to first-line lung cancer.
Pfizer’s LILRB1 x LILRB2 bispecific is about to enter the clinic.
But there are no hard facts, and a Ligand obligation clouds future licensing economics.
Meanwhile, the RayzeBio-originated RYZ101 is back in Action.
Now in Bristol’s hands, BMS-986442 is set to deliver its first clinical data.
An adcom on Imfinzi’s Aegean trial will show whether neoadjuvant and adjuvant benefits must be split out.